In prostate cancer, receptor activation occurs through signal transduction pathways involving tyrosine kinases, NF-κB-inducing kinase (NIK), and IKK, which ultimately leads to phosphorylation and faster turnover of IκBα, the super repressor of NF-κB activation [41]. Here, NFKBIA is linked to prostate carcinoma.